Results 331 to 340 of about 276,897 (341)
Some of the next articles are maybe not open access.
Arkhiv patologii, 2019
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
G A, Frank +8 more
openaire +2 more sources
To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease.The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method.Differences were found in the incidence ...
G A, Frank +8 more
openaire +2 more sources
RSC Medicinal Chemistry
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo +5 more
openaire +2 more sources
Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +3 more sources
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol +3 more
openaire +3 more sources
Science Signaling, 2017
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +1 more source
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire +1 more source
[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Bulletin du cancer, 2018The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers.
Audrey, Monneur +2 more
openaire +1 more source
PD-L1/2: ???????????????????????? ???????????????? ?? ??????????????????
2019???????? ????????????: ???????????? ???????????????? ???????????????????? ???????? ???????????????????????????? ???????????????? ?????????????????? ???????????? PD-L1/2 (program death ligand) ???? ???????????????? ???????????????????? ???????????????????????? (????) ?????????????? ?????????????????????? ???? ??????????????????????. ?????????????????? ??
openaire +1 more source
Mitochondrial PD-L1 modulates cancer immunotherapy
Cell Research, 2023Xiaoming Dai, Jing Liu, Wenyi Wei
openaire +2 more sources
Expression of PD-L1 in mastocytosis
Journal of the American Academy of Dermatology, 2016Lawrence F. Kuklinski, Jinah Kim
openaire +2 more sources